8-KLeadership ChangesRegulation FDExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Mar 12, 2026)

Filed March 12, 2026For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) has announced a significant addition to its Board of Directors through the election of Timothy Wentworth, formerly the chief executive officer of Walgreens Boots Alliance. This appointment, effective March 9, 2026, brings a seasoned executive with extensive experience in the healthcare and retail pharmacy sectors to the company's leadership. Mr. Wentworth has been appointed to serve on the Board's Compensation and Leadership Development Committee and the Quality and Compliance Committee, signaling a focus on critical governance areas. His designation as an independent director, confirmed by both New York Stock Exchange standards and the Company's own guidelines, suggests alignment with best practices in corporate governance. Investors may view this as a positive step towards enhancing board expertise and oversight.

Key Highlights

  • 1Timothy Wentworth, former CEO of Walgreens Boots Alliance, elected as a director.
  • 2Mr. Wentworth appointed to Compensation and Leadership Development Committee.
  • 3Mr. Wentworth appointed to Quality and Compliance Committee.
  • 4The Board determined Mr. Wentworth to be an independent director.
  • 5Mr. Wentworth will receive standard non-employee director compensation.
  • 6Mr. Wentworth received a prorated restricted share unit grant valued at approximately $43,000.

Frequently Asked Questions

Timothy Wentworth is the former chief executive officer of Walgreens Boots Alliance. His election to the Quest Diagnostics Board brings executive leadership experience from a major player in the healthcare and pharmacy retail industry.

Mr. Wentworth has been appointed to serve on the Board's Compensation and Leadership Development Committee and the Board's Quality and Compliance Committee.

Yes, the Board determined that Mr. Wentworth is an independent director, meeting the requirements of the New York Stock Exchange listing standards and the Company's independence guidelines.

Mr. Wentworth will receive compensation in accordance with the Company's standard practices for non-employee directors. This includes a prorated one-time grant of restricted share units valued at approximately $43,000 upon his appointment.